What Leucine Rich Bio does

Leucine Rich Bio is a Bengaluru-based biotechnology company founded in 2014 that operates as India's first and only microbiome-focused genomics business. Its core offering, the BugSpeaks test, sequences a consumer's gut microbiome and generates a personalized three-month diet plan, supported by a proprietary database of 2,000 Indian and 10,000 global microbiome profiles derived from 20,000+ samples analyzed to date. The technology stack includes a proprietary RYCH Index for intestinal microbial health and a gut-microbial-based disease susceptibility assessment method, both covered by filed (pending) patents. A registered clinical trial published in 2024 reported a 20% reduction in HbA1c levels in Type 2 diabetes patients following BugSpeaks recommendations over three months, providing clinically validated outcomes.

The company generates revenue through three primary streams: a one-time direct-to-consumer fee of Rs 10,000 per BugSpeaks kit sold via bugspeaks.com and leucinerichbio.com; a RychBiome supplements line that monetizes the underlying science through consumable products; and contract research services for pharmaceutical companies, CROs, and academic groups. Distribution is direct-to-consumer in India and partner-led internationally, with channel relationships in Malaysia (Trinature Wellness), UAE (Medsol Diagnostics), Philippines, and Brazil. The company is accredited under NABL (the first in India's microbiome testing space), NABH for microbiome research, and ISO/IEC 17025:2017, and is positioning itself as a category-defining platform through sub-brands BugSpeaks, RychBiome, and the World of Microbiome conference, with an Faecal Microbiota Transplant service and skin/oral/vaginal microbiome tests in development.

Name

Leucine Rich Bio

Legal name

Leucine Rich Bio Pvt Ltd

Website

https://leucinerichbio.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Leucine Rich Bio is an India-based microbiome genomics company that sells the BugSpeaks gut microbiome test directly to consumers, develops RychBiome supplements, and offers microbiome research services to pharmaceutical and academic clients across India, Malaysia, UAE, the Philippines, and Brazil.

Ownership category

akta.pro rank

Product category

Microbiome Diagnostics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Food (Health) Supplement Retailers (456191)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal) (HLAAAFAH)

akta.pro secondary industries

Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI), Gut Health & Digestive Nutrition (IBS, GERD, Elimination Diets) (HSADAFAH), Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling) (HLAAAFAK)

Keywords

• Microbiome testing
• Gut microbiome analysis
• Personalized nutrition
• Microbiome diagnostics
• Probiotic supplements

Headquarters

HQ city

Bangalore

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. BugSpeaks Diagnostic Test: Direct-to-consumer microbiome analysis testing service. Customers purchase the BugSpeaks test kit which includes gut microbiome analysis and generates a personalized three-month diet plan based on individual microbial profiles.
2. RychBiome Supplements: Deep science nutritional supplements developed based on microbiome research, sold as a complementary product line to the diagnostic testing service.
3. Collaborative Research Services: Research services for CROs, pharmaceutical companies, and academic researchers including cohort studies, deep science ingredient discovery, and drug discovery targeting the microbiome.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Leucine Rich Bio provides gut microbiome analysis through its BugSpeaks test, which measures bacterial diversity and generates personalized three-month diet plans based on individual microbial profiles. The company also offers RychBiome deep-science nutritional supplements, microbiome-based skincare products, and collaborative research services for pharmaceutical companies and CROs covering cohort studies, ingredient discovery, and microbiome-targeted drug discovery.

Product overview

Leucine Rich Bio operates as a unified platform centered on microbiome science, consisting of BugSpeaks (core microbiome profiling diagnostic), RychBiome (deep science supplements), World of Microbiome (research conference), and upcoming Faecal Microbiota Transplant services. BugSpeaks serves as the primary diagnostic offering generating personalized nutritional recommendations, while RychBiome extends into therapeutic supplements. Research services for CROs and pharma companies cover gut, oral, skin, vaginal, soil, and built environment microbiomes through collaborative research, cohort studies, deep science ingredients, and drug discovery.

Differentiator

Problem solved

Functional benefit

Brands

• BugSpeaks: Microbiome profiling platform offering gut microbiome analysis with personalized nutritional recommendations
• RychBiome
• World of Microbiome

Products and services

• BugSpeaks Microbiome profiling test that measures bacterial diversity and generates personalized three-month diet plans based on individual microbial profiles for personalized nutrition and preventive healthcare. Sold directly to consumers.
• RychBiome Supplements
• Microbiome-based Skincare Product India's first microbiome-based skincare product, leveraging the company's microbiome science expertise to enter the dermatology and skincare market.
• Collaborative Research Services Research services for CROs, pharmaceutical companies, and academic researchers including cohort studies, deep science ingredient discovery, and drug discovery targeting the microbiome. Covers gut, oral, skin, vaginal, soil, and built environment microbiomes.

Quantifiable outcome

• 20% reduction in HbA1c levels in Type 2 diabetes patients following BugSpeaks nutritional recommendations for 3 months
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Trinature WellnesscoreChannel Partner/ Reseller/ DistributorPartnership with Trinature Wellness to launch BugSpeaks microbiome analysis test in Malaysia, expanding the company's presence in Southeast Asia through a local distribution partner.
• Medsol Diagnostics UAEcoreChannel Partner/ Reseller/ DistributorPartnership with Medsol Diagnostics in UAE to advance microbiome health solutions in the Middle East region, leveraging local healthcare infrastructure and market access.
• International Distribution Partners (Philippines, Brazil, UAE)minorChannel Partner/ Reseller/ DistributorInternational expansion through partnerships in Philippines, Brazil, and UAE for distribution of BugSpeaks microbiome analysis services in these markets.
• YUN NVminorStrategic or Co-development PartnerMentioned alongside YUN NV as both being key players in the microbiome space, with Leucine Rich Bio's launch of India's first microbiome-based skincare product highlighted as a significant development.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Viome Life Sciences: Viome is a US-based direct-to-consumer microbiome testing company offering gut microbiome analysis with personalized nutrition recommendations. It is the closest global direct competitor to BugSpeaks, operating in the same product category with similar technology (metatranscriptomic sequencing) and targeting health-conscious consumers.
• DayTwo: DayTwo provides microbiome-based personalized nutrition with clinical validation specifically for Type 2 diabetes and metabolic conditions, mirroring Leucine Rich Bio's clinical trial focus on HbA1c reduction. Both companies target the intersection of microbiome analytics and glycemic management.
• ZOE: ZOE is a UK/US consumer health company combining microbiome testing with blood sugar and blood fat analysis to deliver personalized nutrition. Like Leucine Rich Bio, ZOE sells DTC microbiome tests with accompanying diet recommendations, often at premium price points for health-conscious consumers.
• Atlas Biomed: Atlas Biomed is a UK-based microbiome and DNA testing company offering gut microbiome analysis with personalized dietary recommendations. It competes directly in the DTC consumer microbiome testing space and is often compared to Viome and other BugSpeaks-like offerings.
• Sun Genomics: Sun Genomics offers personalized microbiome testing and custom probiotic formulations direct-to-consumer in the US. The combination of microbiome testing plus a supplement line (Floré) is directly analogous to Leucine Rich Bio's BugSpeaks plus RychBiome model.
• Biohm Health: Biohm Health provides gut and vaginal microbiome testing with personalized probiotic and prebiotic recommendations. It overlaps with both Leucine Rich Bio's core gut offering and its planned expansion into vaginal microbiome testing.
• Thryve Inside: Thryve Inside (formerly Thryve) provides gut microbiome testing and analysis services, including white-label microbiome testing for brands. It is comparable to Leucine Rich Bio both in its DTC testing business and its B2B research and co-development services for partner brands and researchers.

Emerging players

• Daye: Daye is a UK-based femtech company offering vaginal microbiome testing alongside period care products. It is an emerging competitor specifically in the vaginal microbiome category that Leucine Rich Bio plans to enter in 2026.
• MapMyGut (by Carbiotix): Carbiotix is a Swedish microbiome testing and prebiotic fiber ingredient company offering gut microbiome analysis. It overlaps with Leucine Rich Bio on the diagnostics side and on the gut-health supplement/ingredient adjacency through RychBiome.
• Siolta Therapeutics: Siolta Therapeutics is a clinical-stage microbiome therapeutics company developing live biotherapeutic products for inflammatory diseases. While focused on therapeutics rather than diagnostics, Siolta is comparable in its deep microbiome R&D approach and represents the kind of therapeutic-direction opportunity Leucine Rich Bio could pursue with its Faecal Microbiota Transplant service.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/LeucineRichBio

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Leucine Rich Bio